Get the Stockscreener App
220.22
2.47%
-5.57
Pre-market:
220.71
0.49
+0.22%
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $220.22, with a volume of 752.45K.
It is down -2.47% in the last 24 hours and down -6.92% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$225.79
Open:
$222.94
24h Volume:
752.45K
Relative Volume:
0.88
Market Cap:
$32.35B
Revenue:
$4.93B
Net Income/Loss:
$1.25B
P/E Ratio:
26.00
EPS:
8.47
Net Cash Flow:
$1.38B
1W Performance:
-1.61%
1M Performance:
-6.92%
6M Performance:
-12.16%
1Y Performance:
+13.64%
1-Day Range:
$217.67
$222.94
1-Week Range:
$217.67
$243.37
52-Week Range:
$172.19
$263.05
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
220.22 | 32.35B | 4.93B | 1.25B | 1.38B | 8.47 |
|
ISRG
Intuitive Surgical Inc
|
497.30 | 177.37B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
223.82 | 64.27B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
88.78 | 43.91B | 9.91B | 1.02B | 665.00M | 2.05 |
|
BAX
Baxter International Inc
|
34.41 | 17.57B | 17.28B | 108.00M | 391.00M | 0.20 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Should you buy this top ASX share in the dip? - MSN
Why Breville, Flight Centre, Orica, and ResMed shares are dropping today - MSN
ResMed CFO Executes Stock Sale Under Rule 10b5-1 Plan - TipRanks
ResMed CFO Brett Sandercock sells $230,360 in company stock By Investing.com - Investing.com South Africa
ResMed CFO Brett Sandercock sells $230,360 in company stock - Investing.com India
Resmed Chief Commercial Officer Offloads $2.3 Million Worth of Shares -March 11, 2025 at 06:27 pm EDT - Marketscreener.com
ResMed Executive Reports Changes in Stock Ownership - TipRanks
ResMed Inc. CEO Reports Stock Transactions Under Rule 10b5-1 Plan - TipRanks
ResMed’s chief commercial officer sells $2.33 million in stock - Investing.com
Resmed unveils unified brand to streamline services - Mass Device
ResMed CEO Michael J. Farrell sells $1.84 million in stock - Investing.com India
Resmed Unveils Unified Brand To Lead The Global Sleep And Health Technology Revolution - Marketscreener.com
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution - The Korea Bizwire
Resmed Consolidating Brands, Product Lines Under Single Name -March 11, 2025 at 09:25 am EDT - Marketscreener.com
Resmed Unveils Comprehensive Brand Evolution to Enhance Global Sleep and Breathing Health Engagement - Nasdaq
Respiratory Inhalers Market to Witness Remarkable Growth with ResMed Inc., Fisher & Paykel Healthcare, Medtronic - openPR
Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD) - Yahoo Finance
ResMed Shows Market Leadership With Jump To 81 RS Rating - Investor's Business Daily
Jones Financial Companies Lllp Grows Stock Holdings in ResMed Inc. (NYSE:RMD) - Defense World
Why APA, Aurelia Metals, Magnetic Resources, and ResMed shares are rising today - MSN
Brokers rate these 2 ASX growth stocks as top buys - MSN
ResMed Inc Officer Plans Sale of Common Shares - TipRanks
ResMed Among Top Stocks For Recent And Long-Term Profit Growth - Investor's Business Daily
ResMed Insiders Sold US$12m Of Shares Suggesting Hesitancy - Simply Wall St
ResMed (NYSE:RMD) Cut to “Hold” at StockNews.com - Defense World
Resmed Inc Announces Proposed Sale of Securities - TipRanks
Citi slaps buy rating on ResMed shares - MSN
Is it Worth Adding ResMed Stock to Your Portfolio Now? - MSN
ResMed (NYSE:RMD) Raised to “Buy” at Citigroup - Defense World
Stifel Nicolaus Issues Pessimistic Forecast for ResMed (NYSE:RMD) Stock Price - Defense World
Europe Sleep Apnea Devices Analysis Report 2025: Market Set - GlobeNewswire
Insider Sell Alert: Peter Farrell Sells 2,000 Shares of ResMed I - GuruFocus.com
Resmed’s Peter Farrell sells $455,420 in stock - Investing.com India
Citigroup Upgrades ResMed (LSE:0KW4) - Nasdaq
ResMed Inc. (NYSE:RMD) Stock Position Lifted by IFP Advisors Inc - Defense World
ResMed (NYSE:RMD) Trading Down 4.3% After Insider Selling - Defense World
Zacks.com featured highlights include Taiwan, Tapestry, ABM Industries, Vertiv and ResMed - Yahoo Finance
Resmed Founder Offloads Shares Worth $500,000; Shares Down 3% -March 05, 2025 at 10:14 pm EST - Marketscreener.com
ResMed Inc. Director Plans Sale of Common Shares - TipRanks
2 ASX healthcare shares rated as top buys - MSN
Citigroup Upgrades ResMed (RMD) - Nasdaq
Beyond The Numbers: 6 Analysts Discuss ResMed Stock - Benzinga
ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally? - Yahoo Finance
Stifel Adjusts Price Target on ResMed to $240 From $250, Maintains Hold Rating -March 05, 2025 at 06:27 am EST - Marketscreener.com
ResMed upgraded to Buy from Neutral at Citi - TipRanks
ResMed Inc Reports Changes in CHESS Depositary Interests for February 2025 - TipRanks
Analyzing ResMed (NYSE:RMD) and Co-Diagnostics (NASDAQ:CODX) - Defense World
ResMed’s global general counsel sells $14,982 in stock By Investing.com - Investing.com Canada
ResMed Inc. Reports Changes in Beneficial Ownership - TipRanks
Stifel cuts ResMed stock price target to $240 on CPAP market concerns By Investing.com - Investing.com South Africa
Stifel cuts ResMed stock price target to $240 on CPAP market concerns - Investing.com
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):